Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Stock markets trade flat
Tue, 30 Jun 11:30 am

The Indian stock markets have flat in the morning session as investors have remained concerned about the Greece outcome. Selling pressure is seen in IT sector and buying interest is seen in Pharmaceutical stocks.

The BSE-Sensex is trading up by 30 points (0.1%) and the NSE-Nifty is trading up by 10 points (0.1%). The BSE Mid Cap index is trading up by 91 points (0.86%), while the BSE Small Cap index is trading up by 74 points (0.67%). The rupee is trading at 63.74 to the US dollar. Gold and Silver are trading at Rs 26,600 per 10 grams & Rs 35,670 per kilogram respectively.

PSU banking stocks are trading on a mixed note with Corporation Bank trading up by 2.3% and Andhra Bank trading down by 2.4%. Banks have made a proposal to lower the provisions which is required to be made on housing loans. The issue was discussed with Reserve Bank of India (RBI) and the government at a performance review meeting which was held earlier this month. This step could help the banks to bring down the interest rates on housing loans and boost the demand in the struggling construction sector. Currently the interest rates on home loan have come down to single digits and stands at around 9.75%. However it is still seen to be expensive by the borrowers. This move if approved by the RBI could help to reduce the interest rates further.

Stocks in India pharma sector are trading on a positive note with Sun Pharma and Glenmark Pharma leading the winners. DrReddy's Laboratories have initiated a voluntary recall of some drugs which are used to treat seizure and hypertension from the US market. It has been recalled as it failed the dissolution tests. This drug has been recalled under the 'class-II' classification. Certain tablets such as Amlodipine Besylate and Atorvastatin Calcium, which are used to treat high blood pressure or chest pain, have also been recalled as these were close to their expiry dates. DrReddy's Laboratories is trading down by 0.2%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Stock markets trade flat". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.